

Patient Safety Component—Annual Facility Survey for IRF

Instructions for this form are available at: <u>http://www.cdc.gov/nhsn/forms/instr/TOI-57.151-IRF.pdf</u>

*required for saving			Tracking #:	
Facility ID:			*Survey Year:	
Facility Characteristics (con	npleted by Infection Preventi	ionist)		
*Ownership (check one):				
□ For profit	\Box Not for profit, including chu	urch	□ Government	Veterans Affairs
*Affiliation (check one):				
🗆 Hospital System	Independent	🗆 Mul	ti-facility organization	(specialty hospital network)
*How would you describe your	licensed inpatient rehabilitation	n facility? ((check one)	
🗆 Free	e-standing	🗆 Hea	althcare facility based	
In the previous calendar year,	indicate the following counts fo	r the Reha	abilitation Facility:	
*Total number of rehab beds:				
*Average daily census:				
*Number of patient days:				
*Average length of stay:				
*Indicate the number of admiss sum to the total number of adm a. Traumatic spinal cord of b. Non-traumatic spinal cord c. Stroke: d. Brain dysfunction (non- e. Other neurologic condi etc.):	nissions listed below) dysfunction: ord dysfunction:		-	bilitation categories (<u>must</u>
,	incl. fracture, joint replacement	, other):		
g. All other admissions:		ŗ		
*Total number of admissions: *Number of admission	s on a ventilator			
	\leq 18 years old) admissions:			
Facility Microbiology Labor	atory Practices (completed w	vith input	from Microbiology	Laboratory Lead)

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

CDC 57.151 (Front) Rev. 8, v11.1

NHSN NATIONAL HEALTHCARE SAFETY NETWORK			Form Approved OMB No. 0920-0666 Exp. Date: 06/30/2026 www.cdc.gov/nhsn
 *1. Does your facility have its bacterial susceptibility test 1a. If No, where is your fa 	ting?	erforms antimicrobial pility testing performed? (checl	□Yes □No < one)
□ Affiliated medical center	er 🗌 Commercial refer	ral laboratory	al/regional, non-affiliated aboratory
*2. For the following organism (1) Primary susceptibility	ns, indicate which methods ar testing and	e used for:	□ Yes □ No
		uindicate the methods used a	t the outside laboratory
Use the testing codes liste	d below the table.		t the outside laboratory.
Pathogen (1) Primary	(2) Secondary	Comments
Enterobacterales _			
Pseudomonas aeruginosa _			
Acinetobacter baumanni complex –			
1 = Kirby-Bauer disk diffusion	4 = Sensititre	7 = Agar dilution me	ethod
2 = Vitek (Legacy)	5.1 = MicroScan WalkAway	10 = Gradient Diluti	on Strip (for example E test)
2.1 = Vitek 2	5.2 = MicroScan autoSCAN	13 = Other (describ	e in Comments section)
3.1 = BD Phoenix	6 = Other broth microdilutio	n method	
 *3. Does either the primary of (check all that apply): 	secondary/supplemental ant	imicrobial susceptibility testing	(AST) include the following
Drug	also send out any antimicrobial susceptibility testing (check one) Yes No organisms, indicate which methods are used for: applemental, or confirmatory testing (if performed). aboratory Practices (continued) does not perform susceptibility testing, indicate the methods used at the outside laboratory. does not perform susceptibility testing, indicate the methods used at the outside laboratory. Comments (1) Primary (2) Secondary Comments osa		
Cefiderocol			
Ceftazidime-Avibactam			
Ceftolozane-Tazobactam			
Colistin			

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

CDC 57.151 (Front) Rev. 8, v11.1

		Form Approved OMB No. 0920-0666 Exp. Date: 06/30/2026 www.cdc.gov/nhsn
ed revised breakpoints	recommended by CLSI for the follo	owina:
	-	-
for <i>Enterobacterales</i> in	2010	🗆 Yes 🛛 No
r <i>Enterobacterale</i> s <u>in</u> 2	012	🗆 Yes 🛛 No
for Pseudomonas aeru	iginosa <u>in</u> 2012	🗆 Yes 🛛 No
s for Pseudomonas ae	eruginosa <u>in</u> 2019	🗆 Yes 🛛 No
s for Enterobacterales	<u>in</u> 2019	🗆 Yes 🛛 No
rial isolates for presen	ce of carbapenemase? (this does	🗆 Yes 🛛 No
	· · · · ·	
•	esistant	
ces		
		CIM/CIM
		ARBA 5
	-	
□ Pseudom cial or laboratory deve l bloodstream infection erigene, etc. wided information obtained i will be held in strict confide ne individual, or the instituti	in this surveillance system that would perminence, will be used only for the purposes s	inetobacter baumannii ection of antimicrobial lable systems include it identification of any individual or stated, and will not otherwise be
	ed revised breakpoints sporin and monobacta for Enterobacterales in r Enterobacterales in 2 for Pseudomonas aerus s for Pseudomonas aerus s for Pseudomonas aerus s for Pseudomonas aerus s for Pseudomonas aerus instrument expert rules ne if carbapenemase p arbapenem results to re ractices (continued) IIC results without an in e in the interpretation of ces ely performed to detect PCR)	Image: Section of the section of th

NATIONAL HEALT SAFETY NETW	THCARE www.cdc.gov/nhsn
	No [if checked, skip questions 7 and 8]
6a. If Y	'es, which test panel(s) does your facility use? (check all that apply)
	Accelerate PhenoTest BC 🛛 BioFire FilmArray BCID 🗌 BioFire FilmArray BCID II
	Cepheid Xpert MRSA/SA BC 🛛 GenMark ePlex BCID-GP 🗌 GenMark ePlex BCID-GN
	GenMark ePlex BCID-FP 🛛 Luminex Verigene BC-GP 🗌 Luminex Verigene BC-GN
	MALDI-TOF MS directly from positive blood culture (e.g., SepsiTyper)
	MALDI-TOF MS based antimicrobial resistance detection
	T2Biosystems T2Bacteria 🛛 T2Biosystems T2Candida 🗌 T2Biosystems T2Resistance
	Other Commercial Test(s) (Leave Comment)
	Other Laboratory Developed Test(s) (Leave Comment)
	enario where the <i>mecA</i> resistance marker and <i>Staphylococcus aureus</i> are detected by rapid molecular in a blood specimen, select the procedure(s) your facility conducts. (check one)
	Our laboratory does not perform <i>mecA</i> testing using rapid molecular methods. [If checked, skip question 7a.]
	Culture based phenotypic antimicrobial susceptibility testing is not performed. [If checked, skip question 7a.]
	Culture based phenotypic antimicrobial susceptibility testing is performed. A text indicating results of the corresponding rapid molecular testing and/or the interpretation of the rapid molecular testing result is added to the phenotypic test result.
	Culture based phenotypic antimicrobial susceptibility testing is performed. No text indicating
7 - 16 -	corresponding rapid molecular testing and/or interpretation is added.
blo	oth rapid molecular and culture based phenotypic antimicrobial susceptibility testing are performed for a od specimen to detect drug resistance in <i>Staphylococcus aureus</i> , and discordance is found between their sults, how are results reported? (check one)
	Further testing is not pursued. Results are reported separately.
	Further testing is not pursued. The phenotypic result is overridden by the rapid molecular test result when an antimicrobial resistance marker is detected.
Facility Micro	biology Laboratory Practices (continued)
	Further testing is performed to identify the reason for the discordance. Results are modified based on the
	further analysis.
	enario where the <i>bla_{CTX-M}</i> (CTX-M) resistance marker and <i>Escherichia coli</i> are detected by rapid molecular
_	in a blood specimen, select the procedure(s) your facility conducts. (check one)
	Our laboratory does not perform <i>bla_{CTX-M}</i> (CTX-M) testing using rapid molecular methods. [If checked, skip questions 8a]
institution is collect disclosed or release	identiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or ted with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be sed without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health ic 242b, 242k, and 242m(d)).

CDC 57.151 (Front) Rev. 8, v11.1



□ No

□ Yes

- Culture based phenotypic antimicrobial susceptibility testing is not performed. [If checked, skip question 8a.]
- □ Culture based phenotypic antimicrobial susceptibility testing is performed. A text indicating results of the corresponding rapid molecular testing and/or the interpretation of the rapid molecular testing result is added to the phenotypic test result.
- □ Culture based phenotypic antimicrobial susceptibility testing is performed. No text indicating corresponding rapid molecular testing and/or interpretation is added.
- 8a. If both rapid and culture based phenotypic antimicrobial susceptibility testing are performed for a blood specimen to detect drug resistance in *Escherichia coli* and discordance is found between their results, how are results reported? (check one)
 - $\hfill\square$ Further testing is not pursued. Results are reported separately.
 - □ Further testing is not pursued. The phenotypic result is overridden by the rapid molecular test result when an antimicrobial resistance marker is detected.
 - □ Further testing is performed to identify the reason for the discordance. Results are modified based on the further analysis.

*9. Does your facility perform extended-spectrum beta-lactamase (ESBL) testing for *E. coli, Klebsiella oxytoca* or

Proteus mirabilis routinely or using a testing algorithm?

- 9a. If Yes, indicate what is done if ESBL is detected: (check one)
 - $\hfill\square$ Change susceptible Cefotaxime/Ceftriaxone/Cefepime results to resistant
 - \Box No changes are made in the interpretation of cephalosporins with a note of ESBL
 - □ Suppress cephalosporin susceptibility results
- *10.Where is yeast identification performed for specimens collected at your facility? (check one)
 - □ On-site laboratory
 - □ Affiliated medical center
 - □ Commercial referral laboratory
 - □ Other local/regional, non-affiliated reference laboratory
 - □ Yeast identification not available (specifically, yeast identification is not performed onsite or at any affiliate/commercial/other laboratory) [If checked, skip questions 11-15]

Answer questions 11-15 for the laboratory that *performs yeast identification for your facility:*

*11. Which of the following methods are used for yeast identification? (check all that apply)

- □ MALDI-TOF MS System (Vitek MS)
- 🗆 MicroScan

□ MALDI-TOF MS System (Bruker Biotyper)

□ Non-automated Manual Kit (for example, API 20C, RapID,

Germ Tube, PNA-FISH, etc.)

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

CDC 57.151 (Front) Rev. 8, v11.1

NATIONAL HEALT			Form Approved OMB No. 0920-0666 Exp. Date: 06/30/2026 www.cdc.gov/nhsn
			sequencing
	Phoenix		r (specify):
Facility Micro	biology Laboratory Practi	ces (continued)	
*12.Does t	he laboratory routinely use c	hromogenic agar for	the identification or differentiation of Candida isolates?
🗆 Yes	□ No	🗆 Unk	nown
*13. <i>Candia</i> that ap		following body sites	are usually fully identified to the species level? (check all
🗆 Bloc	bd		□ Respiratory
□ Othe	er normally sterile body site	(for example, CSF)	Other (specify):
🗆 Urin	e		\square None are fully identified to the species level
*14.Does t	he laboratory employ any mo	plecular tests to ident	tify Candida from blood specimens?
□ Yes		Unk	
14a.			y <i>Candida</i> from blood specimens?
	T2Candida Panel		
	BioFire BCID		
	GenMark ePlex BCID		
	Other, specify:		
	Unknown		
14b.	If yes and you get a positiv	e result, does this lal	o culture the blood to obtain an isolate?
	Yes, always		
	Yes, with clinical order		
	No		
	Unknown		
*15.Where		esting (AFST) perform	ned for specimens collected at your facility? (check one)
			nal, non-affiliated reference laboratory
	d medical center	-	le (specifically, AFST is not performed onsite or at any
□ Comme	rcial reference laboratory		/other laboratory) [if selected, skip questions 16 -19]
-			<u>ms AFST for your facility</u> : (AFST), excluding Amphotericin B ? (check all that
	h microdilution with ory developed plates	☐ YeastOne (Ther Sensititre [™])	mo Scientific™ □ Gradient diffusion (E test)
institution is collect disclosed or release	ted with a guarantee that it will be	e held in strict confidence	his surveillance system that would permit identification of any individual or e, will be used only for the purposes stated, and will not otherwise be in accordance with Sections 304, 306 and 308(d) of the Public Health
CDC 57.151 (Front	i) Rev. 8, v11.1		
searching existing may not conduct on number. Send con	data sources, gathering, and main or sponsor, and a person is not re mments regarding this burden esti	taining the data needed, equired to respond to a c mate or any other aspect	e 89 minutes per response, including the time for reviewing instructions, and completing and reviewing the collection of information. An agency ollection of information unless it displays a currently valid OMB control of this collection of information, including suggestions for reducing this GA 30333, ATTN: PRA (0920-0666).
			Page 6 of 30

NHSN NATIONAL HEALTHCARE SAFETY NETWORK			Exp	Form Approved MB No. 0920-0666 D. Date: 06/30/2026 www.cdc.gov/nhsn
□ Vitek (bioMerieux)	\Box Other (specify):		Unknown	
*17.What method is used for antifu	ngal susceptibility testing (/	AFST) of Amphoter	icin B? (check all tha	t apply)
Broth microdilution with laboratory developed plates	□ YeastOne (Therm Sensititre™)	o Scientific™	□ Gradient diffusion	(E test)
\Box Vitek (bioMerieux)	\Box Other (specify):		Unknown	
*18.AFST is performed for which o	f the following antifungal dr	ugs? (check all that	apply)	
□ Fluconazole	□ Voriconazole			
Posaconazole	🗌 Micafungin		🗆 Anidulafungin	
🗆 Caspofungin	□ Amphotericin	в	☐ Flucytosine	
□ Other, specify:			-	
	reations (continued)			
Facility Microbiology Laboratory P	ractices (continued)			
*19.AFST is performed on fungal is	solates in which of the follow	wing situations? (che	eck only one box per i	row)
	Performed automatically	Performed with a clinician's order	Not performed	Unknown
Blood				
Other normally sterile body				
site (for example, CSF)				
Urine				
Respiratory				
Other (specify):				
*20.Is this laboratory developing an tested in this laboratory?	ntibiograms or other reports	to track susceptibili	ty trends for <i>Candida</i>	spp. isolates
□ Yes □ No	🗌 Unkno	wn		
*21.What is the primary testing me laboratory where your facility's		•••	lity's laboratory or the	outside
Enzyme immunoassay	(EIA) for toxin			
Cell cytotoxicity neutra	lization assay			
Nucleic acid amplificat	ion test (NAAT) (for examp	le, PCR, LAMP)		
□ NAAT plus EIA, if NAA	T positive (2-step algorithm	1)		
Glutamate dehydroger	nase (GDH) antigen plus El	A for toxin (2-step al	gorithm)	
□ GDH plus NAAT (2-ste	ep algorithm)			
Assurance of Confidentiality: The voluntarily pro institution is collected with a guarantee that it disclosed or released without the consent of th Service Act (42 USC 242b, 242k, and 242m(d)).	will be held in strict confidence,	will be used only for the	purposes stated, and wil	I not otherwise be
CDC 57.151 (Front) Rev. 8, v11.1				
Public reporting burden of this collection of info searching existing data sources, gathering, and may not conduct or sponsor, and a person is number. Send comments regarding this burde burden to CDC, Reports Clearance Officer, 1600	maintaining the data needed, an not required to respond to a colle n estimate or any other aspect of	d completing and review ection of information unle this collection of information	ing the collection of inforn ess it displays a currently ation, including suggestion	nation. An agency valid OMB control
				Page 7 of 30



- GDH plus EIA for toxin, followed by NAAT for discrepant results
- □ Toxigenic culture (*C. difficile* culture followed by detection of toxins)
- □ Other (specify):
- *22.Indicate the primary and definitive method used to identify microbes from blood cultures collected in your facility. (check one)
 - □ MALDI-TOF MS System (Vitek MS)
 - □ MALDI-TOF MS System (Bruker Biotyper)
 - □ Automated Instrument (for example, Vitek, MicroScan, Phoenix, OmniLog, Sherlock, etc.)
 - □ Non-automated Manual Kit (for example, API, Crystal, RapID, etc.)
 - □ Rapid Identification (for example, Verigene, BioFire FilmArray, PNA-FISH, Gene Xpert, etc.)
 - □ 16S rRNA Sequencing
 - Other (specify): _____
 - □ None

*23.Indicate any additional secondary methods used for microbe identification from blood cultures collected in your facility (for example, a rapid method that is confirmed with the primary method, a secondary method if the primary method fails to give an identification, or a method that is used in conjunction with the primary method). (check all that apply)

- □ MALDI-TOF MS System (Vitek MS)
- □ MALDI-TOF MS System (Bruker Biotyper)
- Automated Instrument (for example, Vitek, MicroScan, Phoenix, OmniLog, Sherlock, etc.)
- □ Non-automated Manual Kit (for example, API, Crystal, RapID, etc.)

Facility Microbiology Laboratory Practices (continued)

- □ Rapid Identification (for example, Verigene, BioFire FilmArray, PNA-FISH, Gene Xpert, etc.)
- □ 16S rRNA Sequencing
- Other (specify): ______
- □ None

Infection Control Practices (completed with input from Hospital Epidemiologist and/or Quality Improvement Coordinator)

*24.Number or fraction of infection preventions (IPs) in facility:

- a. Total hours per week performing surveillance:
- b. Total hours per week for infection control activities other than surveillance:
- *25.Number of fraction of full-time employees (FTEs) for a designated hospital epidemiologist (or equivalent role) affiliated with your facility:
- *26.Is it a policy in your facility that patients infected or colonized with MRSA are routinely placed in contact

precautions while these patients are in your facility? (check one)

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

CDC 57.151 (Front) Rev. 8, v11.1

- TIONAL HEALTHCARE SAFETY NETWORK
 - □ Yes
 - 🗆 No
 - $\hfill\square$ Not applicable: my facility never admits these patients
 - 26a. If Yes, check the type of patients that are routinely placed in contact precautions while in your facility (check one):
 - $\hfill\square$ All infected and all colonized patients
 - $\hfill\square$ Only all infected patients
 - □ Only infected or colonized patients with certain characteristics (check all that apply)
 - \Box Patients admitted to high risk settings
 - $\hfill\square$ Patients at high risk for transmission
- *27.Is it a policy in your facility that patients infected or colonized with VRE are routinely placed in contact precautions while these patients are in your facility? (check one)
 - □ Yes
 - 🗆 No
 - $\hfill\square$ Not applicable: my facility never admits these patients
 - 27a. If Yes, check the type of patients that are routinely placed in contact precautions while in your facility (check one):
 - $\hfill\square$ All infected and all colonized patients
 - $\hfill\square$ Only all infected patients
 - □ Only infected or colonized patients with certain characteristics (check all that apply)
 - $\hfill\square$ Patients admitted to high risk settings
 - \Box Patients at high risk for transmission
- *28.Is it a policy in your facility that patients infected or colonized with CRE (regardless of confirmatory testing for carbapenemase production) are routinely placed in contact precautions while these patients are in your facility? (check one)
 - □ Yes
 - 🗆 No
 - $\hfill\square$ Not applicable: my facility never admits these patients

Infection Control Practices (continued)

- 28a. If Yes, check the type of patients that are routinely placed in contact precautions while in your facility (check one):
 - $\hfill\square$ All infected and all colonized patients

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

CDC 57.151 (Front) Rev. 8, v11.1



- □ Only all infected patients
- □ Only infected or colonized patients with certain characteristics (check all that apply)

 \Box Patients admitted to high risk settings

 \Box Patients at high risk for transmission

- *29.Is it a policy in your facility that patients infected or colonized with suspected or confirmed ESBL-producing or extended spectrum cephalosporin resistant *Enterobacterales* are routinely placed in contact precautions while these patients are in your facility? (check one)
 - □ Yes
 - □ No
 - □ Not applicable: my facility never admits these patients
 - 29a. If Yes, check the type of patients that are routinely placed in contact precautions while in your facility (check one):
 - $\hfill\square$ All infected and all colonized patients
 - \Box Only all infected patients
 - Only infected or colonized patients with certain characteristics (check all that apply)

 \Box Patients admitted to high risk settings

- \Box Patients at high risk for transmission
- *30.Does your facility routinely perform screening testing (culture or non-culture) for CRE? This includes screening for patients at your facility performed by public health laboratories and commercial laboratories.

🗆 Yes

- 30a. If Yes, in which situations does the facility routinely perform screening testing for CRE? (check all that apply)
 - $\hfill\square$ Surveillance testing at admission for all patients
 - □ Surveillance testing of epidemiologically-linked patients of newly identified CRE patients (for example, roommates)
 - □ Surveillance testing at admission of high-risk patients (for example, admitted from LTAC or LTCF)
 - □ Surveillance testing at admission of patients admitted to high-risk setting (for example, ICU)
 - □ Surveillance testing of all patients in the facility or in a specific high-risk settings (for example, ICU) at prespecified intervals (for example, weekly point prevalence survey)
 - □ Other (specify):
- 30b. If Yes, what method is routinely used by the lab conducting CRE testing of screening swabs form your facility? (check all that apply)
 - □ Culture-based methods

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

CDC 57.151 (Front) Rev. 8, v11.1

	Ν	H	S	Ν
NATIO SAI	NAL	HEA		ARE

□ PCR

□ Other (specify): ____

*31.Does the facility routinely perform screening testing (culture or non-culture) for Candida auris? This includes screening for patients at your facility performed by public health laboratories and commercial laboratories.

□ Yes □ No

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

CDC 57.151 (Front) Rev. 8, v11.1



Infection Control Practices (continued)

31a.	If Yes, in which	situations does	the facility routinel	y perform	screening	testing for	Candida auris?	(check
al	l that apply)							

- □ Surveillance testing at admission for all patients
- □ Surveillance testing of epidemiologically-linked patients of newly identified *Candida auris* patients (for example, point prevalence surveys in response to a case, patients in the same room or unit as a case)
- □ Surveillance testing at admission of high-risk patients (check all that apply)

□ Patients admitted from long-term acute care (LTAC) or long-term care facility (LTCF)

□ Patients with recent (for example, within 6 months) overnight hospital stay outside the United States

 \Box Patients admitted to high-risk settings (for example, ICU)

 \Box Other (specify): ____

- □ Surveillance testing of all patients in the facility or in a specific high-risk settings (for example, ICU) at prespecified intervals (for example, weekly point prevalence survey)
- □ Other (specify):
- 31b. If Yes, what method is routinely used by the lab conducting *Candida auris* testing of screening swabs from your facility?
 - \Box Culture-based methods
 - □ PCR
 - □ Other (specify): _

*32. Does the facility routinely perform screening testing (culture or non-culture) for MRSA for any patients admitted?

□ Yes □ No

- 32a. If Yes, in which situations does the facility routinely perform screening testing for MRSA? (check all that apply)
 - $\hfill\square$ Surveillance testing at admission for all patients
 - Surveillance testing at admission of high-risk patients (for example, admitted from long-term acute care [LTAC] or long-term care facility [LTCF], or dialysis patients)
 - □ Surveillance testing at admission of patients admitted to high-risk setting (for example, ICU)
 - □ Surveillance testing of pre-operative patients to prevent surgical site infections
 - □ Other (specify): _
- *33.Does your facility have a policy to routinely use chlorhexidine bathing for any adult patients to prevent infection or transmission of MDROs at your facility?
 - □ Yes □ No

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

CDC 57.151 (Front) Rev. 8, v11.1



🗆 No

*34.Does the facility have a policy to routinely use a combination of topical chlorhexidine <u>AND</u> an intranasal antistaphylococcal agent (mupirocin, iodophor, or an alcohol based intranasal agent) for any adult patients to prevent healthcare-associated infections or reduce transmission of resistant pathogens?

🗆 Yes

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

CDC 57.151 (Front) Rev. 8, v11.1

Antibiotic Stewardship Practices

NATIONAL HEALTHCARE SAFETY NETWORK

(completed with input from Physician and Pharmacist Stewardship Leaders)

*35.Did the antibiotic stewardship leader(s) participate in responding to these questions? (check one)

- □ Yes, pharmacist lead
- □ Yes, physician lead
- □ Yes, both pharmacist and physician leads
- □ Yes, other lead
- 🗌 No

*36. Facility leadership has demonstrated commitment to antibiotic stewardship efforts: (check all that apply)

- Providing stewardship program leader(s) dedicated time to manage the program and conduct daily stewardship interventions.
- □ Allocating resources (for example, IT support, training for stewardship team) to support antibiotic stewardship efforts.
- □ Having a senior executive that serves as a point of contact or "champion" to help ensure the program has resources and support to accomplish its mission.
- □ Presenting information on stewardship activities and outcomes to facility leadership and/or board at least annually.
- □ Ensuring the stewardship program has an opportunity to discuss resource needs with facility leadership and/or board at least annually.
- □ Communicating to staff about stewardship activities, via email, newsletters, events, or other avenues.
- □ Providing opportunities for hospital staff training and development on antibiotic stewardship.
- Providing a formal statement of support for antibiotic stewardship (for example, a written policy or statement approved by the board).
- □ Ensuring that staff from key support departments and groups (for example, IT and hospital medicine) are contributing to stewardship activities.
- \Box None of the above

*37.Our facility has a leader or co-leaders responsible for antibiotic stewardship program management and outcomes.

□ Yes □ No

- 37a. If Yes, what is the position of this leader? (check one)
 - Physician
 - Pharmacist
 - □ Co-led by both Pharmacist and Physician
 - □ Other (for example, RN, PA, NP, etc.; specify): _____

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

CDC 57.151 (Front) Rev. 8, v11.1



- 37b. If Physician or Co-led is selected, which of the following describes your antibiotic stewardship **physician** leader? (check all that apply)
 - □ Has antibiotic stewardship responsibilities in their contract, job description or performance review
 - □ Is physically on-site in your facility (either part-time or full-time)
 - □ Completed an ID fellowship
 - □ Completed a certificate program on antibiotic stewardship
 - Completed other training(s) (for example, conferences or online modules) on antibiotic stewardship
 - \Box None of the above

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

CDC 57.151 (Front) Rev. 8, v11.1



Antibiotic Ste	wardship Practices (cont	inued)		
•		e of antibiotic stewards	neir contract or job description' is selecte hip activities is specified in the physici	
	□ 1-10%	□ 11-25%	□ 26-50%	
	□ 51-75%	□ 76-100%	\Box Not specified	
37d. Iea	If Physician or Co-led is se der spend on antibiotic stev	•	week, what percentage of time does th our facility? (check one)	e physician (co)
	□ 1-10%	□ 11-25%	□ 26-50%	
	□ 51-75%	□ 76-100%		
37e. pha	If Pharmacist or Co-led is s armacist leader? (check all		following describes your antibiotic stewa	ardship
	Has antibiotic stewardship	responsibilities in thei	r contract, job description or performand	ce review
	Is physically on-site in you	r facility (either part-tin	ne or full-time)	
	Completed a PGY2 ID resi	idency and/or ID fellow	<i>i</i> ship	
	Completed a certificate pro	ogram on antibiotic ste	wardship	
		-	ences or online modules) on antibiotic s	tewardship
	None of the above		,	
(co		e for antibiotic steward	contract or job description' is selected (f ship activities is specified in the pharm	•
	□ 1-10%	□ 11-25%	□ 26-50%	
	□ 51-75%	□ 76-100%		
37g. (co			age week , what percentage of time doe in your facility? (check one)	es the pharmacist
	□ 1-10%	□ 11-25%	□ 26-50%	
	□ 51-75%	□ 76-100%		
37h. poi	If Pharmacist or Other is so nt of contact and support fo	•	ility have a designated physician who c ader?	an serve as a
			□ Yes	□ No
institution is collect disclosed or release	ed with a guarantee that it will b	e held in strict confidence,	s surveillance system that would permit identificat will be used only for the purposes stated, and accordance with Sections 304, 306 and 308(d	will not otherwise be
CDC 57.151 (Front) Rev. 8, v11.1			
searching existing may not conduct o number. Send cor	data sources, gathering, and main r sponsor, and a person is not re nments regarding this burden esti	ntaining the data needed, a equired to respond to a col imate or any other aspect o	89 minutes per response, including the time for nd completing and reviewing the collection of in lection of information unless it displays a curren of this collection of information, including sugges A 30333, ATTN: PRA (0920-0666).	formation. An agency ntly valid OMB control



37i. If a pharmacist is **not** the leader or co-leader for the program, is there at least one pharmacist responsible for improving antibiotic use at your facility?

□ Yes □ No

- *38.Our facility has the following priority antibiotic stewardship interventions: (check all that apply)
- □ Prospective audit and feedback for specific antibiotic agents
 - 38a. If Prospective audit and feedback is selected: For which categories of antimicrobials? Answer for the following categories of antimicrobials, *whether or not* they are on formulary. (check all that apply)
 - □ Cefepime, ceftazidime, or piperacillin/tazobactam
 - □ Vancomycin (intravenous)

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).


CDC 57.151 (Front) Rev. 8, v11.1



Antibiotic Stewardship Practices (continued) Ceftazidime/avibactam, ceftolozane/tazobactam, meropenem/vaborbactam, imipenem-cilastatin/relebactam, or cefiderocol □ Fluoroquinolones Daptomycin, linezolid, or other newer anti-MRSA agents Ertapenem, imipenem/cilastatin, or meropenem □ Eravacycline or omadacycline □ Lefamulin □ Aminoglycosides Colistin or polymyxin B □ Anidulafungin, caspofungin, or micafungin □ Isavuconazole, posaconazole, or voriconazole □ Amphotericin B and/or lipid-based amphotericin B □ None of the above 38b. If Prospective audit and feedback is selected: Our antibiotic stewardship program monitors prospective audit and feedback interventions (for example, by tracking antibiotic use, types of interventions, acceptance of recommendations). □ Yes □ Preauthorization for specific antibiotic agents 38c. If Preauthorization is selected: For which categories of antimicrobials? Only answer for categories of antimicrobials that are on formulary. (check all that apply) □ Cefepime, ceftazidime, or piperacillin/tazobactam □ Vancomycin (intravenous) Ceftazidime/avibactam, ceftolozane/tazobactam, meropenem/vaborbactam, imipenem-cilastatin/relebactam, or cefiderocol □ Fluoroquinolones Daptomycin, linezolid, or other newer anti-MRSA agents Eravacycline or omadacycline Lefamulin □ Aminoglycosides Colistin or polymyxin B

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).


CDC 57.151 (Front) Rev. 8, v11.1



Review of culture-proven invasive (for example, bloodstream) infections

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

CDC 57.151 (Front) Rev. 8, v11.1



Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

CDC 57.151 (Front) Rev. 8, v11.1



Antibiotic Stewardship Practices (continued)

- 41a. If Yes is selected: Our facility has in place the following specific 'nursing-based' interventions: (check all that apply)
 - □ Nurses receive training on appropriate criteria for sending urine and/or respiratory cultures.
 - □ Nurses initiate discussions with the treating team on switching from intravenous to oral antibiotics.
 - □ Nurses initiate antibiotic time-out discussions with the treating team.
 - □ Nurses track antibiotic duration of therapy.
 - \Box None of the above
- 41b. If 'Nurses track antibiotic duration of therapy' is selected: Is that information available at the bedside (for example, on a whiteboard in the room)?

🗆 Yes 👘 No

*42.Our stewardship program monitors: (check all that apply)

- □ Antibiotic resistance patterns (either facility- or region-specific), at least annually
- □ Clostridioides difficile infections (or C. difficile LabID events), at least annually
- Antibiotic use in days of therapy (DOT) per 1000 patient days or day present, at least quarterly
- Antibiotic use in defined daily doses (DDD) per 1000 patient days, as least quarterly
- □ Antibiotic expenditures (specifically, purchasing costs), at least quarterly

Antibiotic use in some other way, at least annually (specify):

 \Box None of the above

*43.Our stewardship team provides the following antibiotic use reports to prescribers, at least annually: (check all that apply)

- \Box Individual, prescriber-level reports
- □ Unit- or service-specific reports
- \Box None of the above
 - 43a. If 'Individual, prescriber-level reports' or 'Unit- or service-specific reports' is selected: Our stewardship program uses these reports to target feedback to prescribers about how they can improve their antibiotic prescribing, at least annually.

	∐ Yes	🗆 No
*44.Our facility distributes an antibiogram to prescribers, at least annually.		
	□ Yes	🗆 No
*4F Information on antihistic use antihistic resistance, and storaged bin offerts is remarked to		- 4 4

*45.Information on antibiotic use, antibiotic resistance, and stewardship efforts is reported to hospital staff, at least annually.

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

CDC 57.151 (Front) Rev. 8, v11.1



- *46.Which of the following groups receive education on optimal prescribing, adverse reactions from antibiotics, an antibiotic resistance (for example, Grand Rounds, in-service training, direct instruction) at least annually? (check all that apply)
 - □ Prescribers
 - □ Nursing staff
 - □ Pharmacists
 - \Box None of the above

*47. Are patients provided education on important side effects of prescribed antibiotics?

□ Yes

🗌 No

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

CDC 57.151 (Front) Rev. 8, v11.1



JALL		OKK				
Antib	iotic St	ewardship Practices (continued)				
	47a.	If 'Yes' is selected: How is education	n to patients on	side effects shared? (ch	neck all that apply)	
		\Box Discharge paperwork	🗆 Verba	lly by physician		
		\Box Verbally by nurse	🗆 None	of the above		
		\Box Verbally by pharmacist				
Ontior	nal Anti	biotic Stewardship Practices				
-		the following questions are not r	equired to com	plete the annual surve	ev.	
-		ional information about your facil	-	-	· •	
48.	Antibio	tic stewardship activities are integrat	ed into quality in	nprovement and/or patie	ent safety initiatives	
					□ Yes	🗆 No
		ility accesses targeted remote stewa		e (for example, tele-stew	vardship to obtain fa	acility-
	specific	support for antibiotic stewardship e	forts.			
50	0					□ No
	our ste	wardship program works with the mi apply)	crobiology labor	atory to implement the f	following intervention	ons: (check
		Selective reporting of antimicrobial	susceptibility tes	sting results		
		Placing comments in microbiology	reports to improv	e prescribing		
		None of the above				
51.	Which	committees or leadership entities pro	vide oversight o	of your facility's antibiotic	c stewardship effort	s? (check
	all that	apply)				
		\Box Pharmacy director		utive leadership (for exa	ample, CEO, CMO))
		\Box Pharmacy & therapeutics	🗆 Hosp	bital board		
		□ Patient safety	\Box Othe	r (specify):		
		\Box Quality improvement		9		
acilit	v Wate	r Management Program (WMP) (Co	ompleted with i	nput from WMP team	members.)	
	-	our facility have a water managemer		-	-	of
	-	ella and other opportunistic waterbor		, ,		
	Burkho	Ideria, Stenotrophomonas, nontuber	culous mycobad	teria, and fungi)?		
					\Box Yes	🗆 No
	52a.lf Y	es, who is represented on your facili	ty WMP team?	(check all that apply):		
		Hospital Epidemiologist/Infection Pre	ventionist	□ Compliance/Safety (Officer	
			ventionist		Onicei	
stitution sclosed	is collect or release	dentiality: The voluntarily provided informatio ted with a guarantee that it will be held in s sed without the consent of the individual, or C 242b, 242k, and 242m(d)).	strict confidence, wi	II be used only for the purpo	oses stated, and will no	t otherwise be
DC 57.1	.51 (Front) Rev. 8, v11.1				
		rden of this collection of information is estim data sources, gathering, and maintaining the				

searching existing data sources, gathering, and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS H-21, Atlanta, GA 30333, ATTN: PRA (0920-0666).



- □ Hospital Administrator/Leadership
- □ Facilities Manager/Engineer
- \Box Maintenance Staff
- Equipment/Chemical Acquisition/Supplier
- Environmental Services

- □ Risk/Quality Management Staff
- \Box Infectious Disease Clinician
- \Box Consultant
- \Box Laboratory Staff/Leadership
- Other (specify): _____

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

CDC 57.151 (Front) Rev. 8, v11.1

opportunis infrastructu	facility ever tic waterborn tre)? This ma	e pathoger y include a	d an envi ns could g description	ronmental row and s of buildin	spread in g water sy	ent to identify the facility water stems using text of	system (for exar or basic diagram t	nple, pipir
water supp	ly sources, tr	eatment sy	stems, proc	cessing ste	eps, contro	ol measures, and e	end-use points.	🗆 No
53a.lf Yes,	when was th	e most rece	ent assessn	nent condu	ucted? (ch	eck one)		
□ Within (<1 year	the most rec ago)	ent year		en 1 and 3 and <u><</u> 3 yea		o □ More that years)	n 3 years ago (>3	
modes of	transmission	, patient s	usceptibility	, patient	exposure,	sessment (WICR/ and/or program ent/water-assessr	preparedness?	An examp
							□ Yes	🗆 No
54a. If Y	Yes, when wa	s the most	recent asse	essment co	onducted?	(check one)		
□ Within (<1 year	the most rec ago)	ent year		en 1 and 3 and <u>≤</u> 3 yea		o □ More that years)	n 3 years ago (>3	
*55.Does your	facility regula	rly monitor	the followir	ng parame	ters in the	building water sys	stem(s)?	
limits a	res, Does yo Is determined	ur facility ha I by the wat	ave a plan er manage	ment prog	ram?	s when disinfectar disinfectant(s)? (
	Entry Points	Cold Potable Water	Hot Potable Water Storage	Hot Water Supply	Hot Water Return	Representative Locations Throughout Cold Potable	Representative Locations Throughout Hot Potable	Other (specify)
		Storage Tank(s)	Tank(s)			Building Water System(s)	Building Water System(s)	
Daily			-			System(s)	Building Water System(s)	
Daily Veekly		Tank(s)	Tank(s)			System(s)	System(s)	

CDC 57.151 (Front) Rev. 8, v11.1

Service Act (42 USC 242b, 242k, and 242m(d)).

0000

NHSN



SAFETY NET	WORK								-
Quarterly									
Annually									
Other (specify):									
Water temperature: \Box Yes 55c. If Yes, does your facility have a plan for corrective actions when water temperatures are not within									
ac	cceptable	limits as	determined	by the wat	ter manag	ement pro	gram?	🗆 Yes	🗆 No
55d.	lf Yes,	where an	d how freq	uently does	s your facil	ity monitoi	r water temperatui	re? (check all that	apply)
Facility Wate	er Manag	gement P	rogram (W	/MP) (conti	inued)				
		Entry Points	Cold Potable Water Storage Tank(s)	Hot Potable Water Storage Tank(s)	Hot Water Supply	Hot Water Return	Representative Locations Throughout Cold Potable Building Water System(s)	Representative Locations Throughout Hot Potable Building Water System(s)	Other (specify):
Daily									
Weekly									
Monthly									
Quarterly									
Annually									
Other (specify):									
Water pH: 55e. If Yes, does your facility have a plan for corrective actions when water pH is not within acceptable limits as determined by the water management program? Yes No									
55f. lf	Yes, whe	ere and ho	ow frequent	ly does you	ur facility m	nonitor wa	ter pH? (check all	that apply)	
		Entry Points	Cold Potable Water	Hot Potable Water	Hot Water Supply	Hot Water Return	Representative Locations	Representative Locations	Other (specify):

Points	Potable	Potable	Water	Water	Locations	Locations	(specify):
	Water	Water	Supply	Return	Throughout	Throughout	
	Storage	Storage			Cold Potable	Hot Potable	
	Tank(s)	Tank(s)			Building Water	Building Water	
					System(s)	System(s)	
	1	1	1	1	- , (-)	- , (-)	1

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

CDC 57.151 (Front) Rev. 8, v11.1



of a little the state				
Daily				
Weekly				
Monthly				
Quarterly				
Annually				
Other (specify):				

Heterotrophic plate count (HPC) testing:	🗆 Yes	🗆 No
55g. If Yes, does your facility have a plan for corrective actions when heterotrophic	c plate counts a	are not within
acceptable limits as determined by the water management program?	□ Yes	🗆 No

55h. If Yes, where and how frequently does your facility perform HPC testing? (check all that apply)

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

CDC 57.151 (Front) Rev. 8, v11.1



Facility Water Management Program (WMP) (continued)

	Entry Points	Cold Potable Water Storage Tank(s)	Hot Potable Water Storage Tank(s)	Hot Water Supply	Hot Water Return	Representative Locations Throughout Cold Potable Building Water System(s)	Representative Locations Throughout Hot Potable Building Water System(s)	Other (specify):
Daily								
Weekly								
Monthly								
Quarterly								
Annually								
Other (specify):								

Specific environmental Legionella testing:

□ Yes □ No

□ No

□ Yes

55i. If Yes, does your facility have a plan for corrective actions when environmental tests for *Legionella* are not

within acceptable limits as determined by the water management program?

55j. If Yes, where an how frequently does your facility perform Legionella testing? (check all that apply)

	Entry Points	Cold Potable Water Storage Tank(s)	Hot Potable Water Storage Tank(s)	Hot Water Supply	Hot Water Return	Representative Locations Throughout Cold Potable Building Water System(s)	Representative Locations Throughout Hot Potable Building Water System(s)	Other (specify):
Daily								
Weekly								
Monthly								
Quarterly								
Annually								
Other (specify):								

Specific environmental Pseudomonas testing:

□ Yes □ No

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

CDC 57.151 (Front) Rev. 8, v11.1



55k. If Yes, does your facility have a plan for corrective actions when environmental tests for *Pseudomonas* are not within acceptable limits as determined by the water management program?

55I. If Yes, where an how frequently does your facility perform *Pseudomonas* testing? (check all that apply)

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

CDC 57.151 (Front) Rev. 8, v11.1



Facility Water Management Program (WMP) (continued)

	Entry Points	Cold Potable Water Storage Tank(s)	Hot Potable Water Storage Tank(s)	Hot Water Supply	Hot Water Return	Representative Locations Throughout Cold Potable Building Water System(s)	Representative Locations Throughout Hot Potable Building Water System(s)	Other (specify):
Daily								
Weekly								
Monthly								
Quarterly								
Annually								
Other (specify):								

*56.Does your facility water management program address measures to prevent transmission of pathogens from wastewater premise plumbing to patients?

🗆 Yes

🗆 No

 \Box N/A, my facility does not have a water management program

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

CDC 57.151 (Front) Rev. 8, v11.1